Ardea Biosciences Reports Recent Accomplishments and Announces Third Quarter and Year-to-Date 2009 Financi...(----- ----- ----- ----- ...),Health

Date:11/6/2009

----- ----- ----- ----- Total other income (expense) (237) 279 (691) 1,485 Net loss (2,471) (14,223) (24,537) (42,329) ------ ------- ------- ------- Non-cash dividends on Series A preferred stock - - - (60) ----- ----- ----- ----- Net loss applicable to common stockholders $(2,471) $(14,223) $(24,537) $(42,389) ======= ========= ========= ========= Basic and diluted net loss per share applicable to common stockholders $(0.13) $(0.95) $(1.36) $(2.98) ====== ====== ====== ====== Shares used in computing basic and diluted net loss per share applicable to common stockholders 18,327 15,023 18,062 14,239 ====== ====== ====== ======

                      Condensed Consolidated Balance Sheet Data
                                    (in thousands)


                                                 September 30,  December 31,
                                                     2009          2008
                                                 -------------  ------------
        Cash, cash equivalents and short-term
         investments                               $59,589       $57,743
        Total assets                               $64,121       $61,475
        Total stockholders' equity                 $29,037       $45,958

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Becaus
'/>"/>

SOURCE Ardea Biosciences, Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8
Related medicine technology :

1. Ardea Biosciences Presents Preclinical Anti-Inflammatory Data on its Lead MEK Inhibitor, RDEA119, at the ACG 2008 Annual Meeting
2. Ardea Biosciences to Present Data on Lead MEK Inhibitor, RDEA119, at American College of Gastroenterology Annual Scientific Meeting
3. Ardea Biosciences Advances Lead Product Candidate for the Treatment of Gout, RDEA594, Into Phase 1 Clinical Trial
4. Ardea Biosciences Presents Phase 2a Antiviral Activity Data for Lead HIV Candidate, RDEA806 at XVII International AIDS Conference
5. Ardea Biosciences Reports Additional Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating Up to 1.9 Log Reduction in Plasma Viral Load with Once-Daily Dosing
6. Ardea Announces Progress with HIV Non-Nucleoside Reverse Transcriptase Inhibitor Program
7. Ardea Biosciences Presents Preclinical Data on RDEA119 Demonstrating Favorable Anti-Inflammatory Profile for Potential Use in Ulcerative Colitis
8. Ardea Biosciences Identifies Lead Development Candidate for Gout, RDEA594
9. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
10. Ardea Biosciences Presents Data Demonstrating Favorable Pharmacokinetics and Efficacy for Mitogen-Activated ERK Kinase (MEK) Inhibitors
11. Ardea Biosciences Reports Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating up to 2.0 Log Reduction in Plasma Viral Load